Biohaven to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026
Rhea-AI Summary
Biohaven (NYSE: BHVN) announced that Vlad Coric, M.D., Chairman and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 8:15 a.m. PST (11:15 a.m. EST). The presentation is scheduled for The Westin St. Francis Hotel in San Francisco, California.
Positive
- None.
Negative
- None.
News Market Reaction – BHVN
In the Jan 7 session, BHVN gained 22.04%, reflecting a significant positive market reaction. Argus tracked a peak move of +20.3% during that session. Our momentum scanner triggered 101 alerts that day, indicating very high trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 24 | Clinical trial update | Negative | +3.0% | Phase 2 BHV-7000 MDD trial failed primary endpoint but stock rose modestly. |
| Dec 11 | Clinical data update | Positive | +7.9% | Phase 1 BHV-1510 combo showed high ORR and favorable safety profile. |
| Nov 13 | Offering closing | Negative | +2.7% | Closed upsized equity offering with ~$200M gross proceeds; shares gained. |
| Nov 12 | Offering pricing | Negative | -6.7% | Priced $175M equity offering at $7.50; stock fell following the announcement. |
| Nov 11 | Offering announcement | Negative | +9.4% | Proposed $150M share offering yet shares rose strongly after the news. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows positive price reactions to both favorable trial data and financing events, with several instances where shares rose despite potentially dilutive offerings or negative trial outcomes.
Over the past few months, Biohaven reported multiple financings and clinical updates. In Nov 2025, it announced and then priced and closed a public offering totaling about $175–200M, with mixed market reactions but notable insider and institutional participation. Clinical news included a strong Phase 1 dataset for BHV‑1510 and a Phase 2 BHV‑7000 MDD study that did not meet its primary endpoint, yet shares still gained 2.95%. Today’s conference appearance follows this active period of capital raises and pipeline updates.
Key Terms
nyse financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
About Biohaven
Biohaven is a biopharmaceutical company focused on the discovery, development and commercialization of life-changing treatments in key therapeutic areas, including immunology, obesity, neuroscience and oncology. Biohaven is advancing its innovative portfolio of therapeutics, leveraging its proven drug development experience and multiple proprietary drug development platforms. Biohaven's key clinical and preclinical programs include Kv7 ion channel modulation for epilepsy; MoDE™ and TRAP™ extracellular protein degraders for immunological diseases; and myostatin-activin pathway targeting agents for neuromuscular and metabolic diseases, including SMA and obesity. For more information, visit www.biohaven.com.
Forward-looking Statements
This news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including "continue", "plan", "will", "believe", "may", "expect", "potential first-in-class", "potentially", "groundbreaking" and similar expressions, is intended to identify forward-looking statements. Investors are cautioned that any forward-looking statements, including statements regarding the future development, timing and potential marketing approval and commercialization of development candidates, are not guarantees of future performance or results and involve substantial risks and uncertainties. Actual results, developments and events may differ materially from those in the forward-looking statements as a result of various factors including: the expected timing, commencement and outcomes of Biohaven's planned and ongoing clinical trials; the timing of planned interactions and filings with the FDA; the timing and outcome of expected regulatory filings; complying with applicable US regulatory requirements; the potential commercialization of Biohaven's product candidates; and the effectiveness and safety of Biohaven's product candidates. Additional important factors to be considered in connection with forward-looking statements are described in Biohaven's filings with the Securities and Exchange Commission, including within the sections titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations". The forward-looking statements are made as of the date of this news release, and Biohaven does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
MoDE and TRAP are trademarks of Biohaven Therapeutics Ltd.
Investor Contact:
Jennifer Porcelli
Vice President, Investor Relations
jennifer.porcelli@biohavenpharma.com
+1 (201) 248-0741
Media Contact:
Christy Curran
Sam Brown Inc.
christycurran@sambrown.com
+1 (615) 414-8668
View original content to download multimedia:https://www.prnewswire.com/news-releases/biohaven-to-present-at-the-44th-annual-jp-morgan-healthcare-conference-on-january-12-2026-302654353.html
SOURCE Biohaven Ltd.